Syno Capital

Applied Therapeutics is a biopharmaceutical company focused on developing transformative drugs targeting fatal and debilitating diseases with high unmet medical needs. Its pipeline includes novel product candidates such as AT-007 for rare metabolic diseases like galactosemia, AT-001 for diabetic cardiomyopathy, and AT-003 for diabetic retinopathy.

PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel therapies for cardiopulmonary diseases. Its lead product candidate, PB2452, is a reversal agent for the antiplatelet drug ticagrelor, intended to manage uncontrolled bleeding events or urgent surgeries. PhaseBio is also developing PB1046 for pulmonary arterial hypertension and PB6440 for resistant hypertension.

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company based in Cambridge, Massachusetts, focuses on developing novel T cell receptor therapies for cancer treatment. Founded in 2015 by Dr. Patrick Baeuerle and MPM Capital, TCR2 specializes in engineering T cells to target specific antigens expressed by cancer cells. The company's lead product candidates include TC-210, which targets mesothelin-positive solid tumors such as non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma; and TC-110, targeting CD19-positive B-cell hematological malignancies. TCR2's pipeline also includes candidates for adult acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and follicular lymphoma. The company's approach is distinct from traditional CAR-T cells and other engineered T cell therapies, leveraging a deep understanding of T cell receptor biology to create highly differentiated treatments.

ORIG3N, Inc. is a biotechnology company focused on developing innovative treatments for rare genetically inherited diseases, particularly targeting conditions related to the heart, liver, and neurodegeneration. Founded in 2014 and based in Boston, Massachusetts, ORIG3N utilizes induced pluripotent stem cell technology that allows for the differentiation of cells into any type found in the body. This technology is employed to test drug efficacy, screen for medication toxicity, and create personalized treatment pathways. The company offers a range of products, including LifeProfiles, which provides genetic insights related to fitness, metabolism, and exercise recovery; the Run DNA test for optimizing running performance; AURA, which assesses skin health; and Life Capsule, a repository for blood cells aimed at regenerative medicine development.

Applied Therapeutics is a biopharmaceutical company focused on developing transformative drugs targeting fatal and debilitating diseases with high unmet medical needs. Its pipeline includes novel product candidates such as AT-007 for rare metabolic diseases like galactosemia, AT-001 for diabetic cardiomyopathy, and AT-003 for diabetic retinopathy.

Honor operates a large in-home senior care network and technology platform that connects older adults with professional caregivers and home care agencies to deliver high-quality, personalized care in the comfort of their homes. The company combines scalable workforce management and technology with a network of care providers to coordinate reliable, transparent services that support aging in place. Through strategic expansion, including the 2021 acquisition of Home Instead, Honor leverages its platform and global network to improve quality of life for seniors and support families and care professionals.

ORIG3N, Inc. is a biotechnology company focused on developing innovative treatments for rare genetically inherited diseases, particularly targeting conditions related to the heart, liver, and neurodegeneration. Founded in 2014 and based in Boston, Massachusetts, ORIG3N utilizes induced pluripotent stem cell technology that allows for the differentiation of cells into any type found in the body. This technology is employed to test drug efficacy, screen for medication toxicity, and create personalized treatment pathways. The company offers a range of products, including LifeProfiles, which provides genetic insights related to fitness, metabolism, and exercise recovery; the Run DNA test for optimizing running performance; AURA, which assesses skin health; and Life Capsule, a repository for blood cells aimed at regenerative medicine development.

LungLife AI, Inc. is a clinical diagnostics company based in Thousand Oaks, California, specializing in the early detection and management of lung cancer through the molecular analysis of cancer biomarkers in blood. The company utilizes machine learning and artificial intelligence to enhance the accuracy and efficiency of cancer diagnosis and treatment. LungLife AI offers a range of products, including the LiquidBiopsy platform for isolating rare cells from blood samples and the Everest software for sequence analysis. Additionally, it provides CLIA/CAP lab services, such as the ClearID test for identifying targetable DNA mutations and the NK Vue test for monitoring immune system health. The company's offerings aim to improve treatment stratification and monitoring across all stages of lung cancer. LungLife AI was founded in 2006 and was formerly known as Cynvenio Biosystems, Inc. It also maintains a strategic collaboration with the Institute of Regional Health Research.